News

The biotechnology industry in China is coming of age as a major licencing deal has been signed between RemeGen Co Ltd and Seagen Inc, a Seattle-based company. The deal marks the biggest of all between a western company and...

Moderna, the US biotech firm, has announced that it has initiated clinical trials of a booster that is especially designed to fight out the COVID-19 omicron variant. As per the announcement made by the company, there will be a total...

Abacus Medicine Pharma Services is the new name for the healthcare and pharma services company previously known as Aposave. Simon Estcourt, Managing Director, Abacus Medicine Pharma Services explains the rebranding: “The new brand makes it very clear who we are and...

According to Moderna’s CEO, Stephane Bancel, the company is aiming to bring to the market a combination of COVID-19 and influenza booster in the coming two years. In an official announcement made by him, the single-shot vaccine against the...

As per GlobalData’s Thematic Research ecosystem, pharmaceutical giants Novartis and Pfizer are the best-positioned companies to take advantage of future biosimilars in the pharma landscape. This ecosystem by GlobalData positions companies on a one to five scale, predominantly on the...

Pfizer Inc. and BioNTech SE announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts...

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,  announced that Australia's Therapeutic Goods Administration (TGA) has granted approval for provisional registration of NVX-CoV2373, Novavax' COVID-19 vaccine (adjuvanted), for active immunization to...